Adlai Nortye vs China Pharma
ANL and CPHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANL and CPHI compare
China Pharma keeps more of each dollar of sales as profit, with a net margin of −114% compared with −711% at Adlai Nortye.
China Pharma scores higher on the StockData Score (4 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANL | CPHI |
|---|---|---|
| Size and price | ||
| Market cap | – | $23.4M |
| Share price | $10.85 | $0.543 |
| Change, 1 year | 587% | −64.5% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | 1.68 | 0.89 |
| Employees | – | 221 |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 6.0× |
| P/B | – | 0.6× |
| Growth | ||
| Revenue growth (TTM) | – | −11.0% |
| Revenue growth, 5Y average | – | −17.5% |
| Profitability | ||
| Gross margin | – | 11.8% |
| Operating margin | −714% | −112% (better) |
| Net margin | −711% | −114% (better) |
| FCF margin | −673% | – |
| Return on equity | – | −21.0% |
| Return on invested capital | – | −15.5% |
| Financial health | ||
| Debt / equity | – | 0.05 |
| Interest coverage | −23.3× (better) | −136.5× |
| Current ratio | 0.65 (better) | 0.26 |
| Altman Z-score | – | −0.30 |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 22.1% | 0.47% |
| Held by insiders | 14.7% | 0.00% |
| Insider net buying, 12 months | −$411K | – |
| Short interest, % of float | – | 0.21% |
Go deeper
- ANL stock overview
- ANL income statement
- ANL valuation and score
- CPHI stock overview
- CPHI income statement
- CPHI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.